IFI44L and neoplasm: In contrast to the healthy control group, liver cancer patients show a reduced expression of IFI44L. This gene not only impedes the metastasis, invasion, and resistance of tumor cells to doxorubicin but also restricts their migration and invasion via the met/Src signaling pathway (51).